Clinical outcomes of chemical pleurodesis using a minocycline

Background: Pleurodesis is often used to prevent the re-accumulation of a malignant pleural effusion (MPE). Intrapleural urokinase (IPUK) therapy facilitates lung re-expansion for patients with loculated MPE or a trapped lung that allows subsequent pleurodesis. MPE management has been traditionally...

Full description

Bibliographic Details
Main Authors: Li-Han Hsu, An-Chen Feng, Thomas C. Soong, Jen-Sheng Ko, Nei-Min Chu, Yung-Feng Lin, Shu-Huei Kao
Format: Article
Language:English
Published: SAGE Publishing 2019-04-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/1753466619841231
id doaj-82f120a6322740589d502bbda93cd046
record_format Article
spelling doaj-82f120a6322740589d502bbda93cd0462020-11-25T02:33:59ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46662019-04-011310.1177/1753466619841231Clinical outcomes of chemical pleurodesis using a minocyclineLi-Han HsuAn-Chen FengThomas C. SoongJen-Sheng KoNei-Min ChuYung-Feng LinShu-Huei KaoBackground: Pleurodesis is often used to prevent the re-accumulation of a malignant pleural effusion (MPE). Intrapleural urokinase (IPUK) therapy facilitates lung re-expansion for patients with loculated MPE or a trapped lung that allows subsequent pleurodesis. MPE management has been traditionally regarded as a symptomatic treatment. We tried to evaluate their impact on patient survival. Methods: There were 314 consecutive patients with symptomatic MPE that underwent minocycline pleurodesis with ( n = 109) and without ( n = 205) the antecedent IPUK therapy between September 2005 and August 2015, who were recruited for the pleurodesis outcome and survival analysis. Results: The rate of successful pleurodesis was similar between the simple pleurodesis group and the IPUK therapy group followed by the pleurodesis group (69.0% versus 70.5%; p = 0.804). The patients who succeeded pleurodesis had a longer survival rate than those who failed in either the simple pleurodesis group (median, 414 versus 100 days; p < 0.001) or the IPUK therapy followed by pleurodesis group (259 versus 102 days; p < 0.001). The survival differences remained when the lung and breast cancer patients were studied separately. Conclusion: Successful pleurodesis translated into a better survival rate that promotes performing pleurodesis on lung re-expansion. The apparent shorter survival of the patients with loculated MPE or trapped lung, and those that did not respond to the IPUK therapy, lowered the probability of the survival benefit through the simple physical barrier by the fibrin formation to prevent the tumor spreading. The successfully induced inflammatory response by minocycline is supposed to prohibit the tumor invasion and metastasis. Further studies are warranted to clarify the mechanism and provide opportunities to develop novel therapeutic strategies.https://doi.org/10.1177/1753466619841231
collection DOAJ
language English
format Article
sources DOAJ
author Li-Han Hsu
An-Chen Feng
Thomas C. Soong
Jen-Sheng Ko
Nei-Min Chu
Yung-Feng Lin
Shu-Huei Kao
spellingShingle Li-Han Hsu
An-Chen Feng
Thomas C. Soong
Jen-Sheng Ko
Nei-Min Chu
Yung-Feng Lin
Shu-Huei Kao
Clinical outcomes of chemical pleurodesis using a minocycline
Therapeutic Advances in Respiratory Disease
author_facet Li-Han Hsu
An-Chen Feng
Thomas C. Soong
Jen-Sheng Ko
Nei-Min Chu
Yung-Feng Lin
Shu-Huei Kao
author_sort Li-Han Hsu
title Clinical outcomes of chemical pleurodesis using a minocycline
title_short Clinical outcomes of chemical pleurodesis using a minocycline
title_full Clinical outcomes of chemical pleurodesis using a minocycline
title_fullStr Clinical outcomes of chemical pleurodesis using a minocycline
title_full_unstemmed Clinical outcomes of chemical pleurodesis using a minocycline
title_sort clinical outcomes of chemical pleurodesis using a minocycline
publisher SAGE Publishing
series Therapeutic Advances in Respiratory Disease
issn 1753-4666
publishDate 2019-04-01
description Background: Pleurodesis is often used to prevent the re-accumulation of a malignant pleural effusion (MPE). Intrapleural urokinase (IPUK) therapy facilitates lung re-expansion for patients with loculated MPE or a trapped lung that allows subsequent pleurodesis. MPE management has been traditionally regarded as a symptomatic treatment. We tried to evaluate their impact on patient survival. Methods: There were 314 consecutive patients with symptomatic MPE that underwent minocycline pleurodesis with ( n = 109) and without ( n = 205) the antecedent IPUK therapy between September 2005 and August 2015, who were recruited for the pleurodesis outcome and survival analysis. Results: The rate of successful pleurodesis was similar between the simple pleurodesis group and the IPUK therapy group followed by the pleurodesis group (69.0% versus 70.5%; p = 0.804). The patients who succeeded pleurodesis had a longer survival rate than those who failed in either the simple pleurodesis group (median, 414 versus 100 days; p < 0.001) or the IPUK therapy followed by pleurodesis group (259 versus 102 days; p < 0.001). The survival differences remained when the lung and breast cancer patients were studied separately. Conclusion: Successful pleurodesis translated into a better survival rate that promotes performing pleurodesis on lung re-expansion. The apparent shorter survival of the patients with loculated MPE or trapped lung, and those that did not respond to the IPUK therapy, lowered the probability of the survival benefit through the simple physical barrier by the fibrin formation to prevent the tumor spreading. The successfully induced inflammatory response by minocycline is supposed to prohibit the tumor invasion and metastasis. Further studies are warranted to clarify the mechanism and provide opportunities to develop novel therapeutic strategies.
url https://doi.org/10.1177/1753466619841231
work_keys_str_mv AT lihanhsu clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT anchenfeng clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT thomascsoong clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT jenshengko clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT neiminchu clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT yungfenglin clinicaloutcomesofchemicalpleurodesisusingaminocycline
AT shuhueikao clinicaloutcomesofchemicalpleurodesisusingaminocycline
_version_ 1724810947486285824